

ASX ANNOUNCEMENT

Manufacturing Strategy Update and Queensland Government Support

- Analytica to bring manufacturing responsibility in-house.
- Queensland Government financial support through grant funding under the Advance Queensland Industry Attraction Fund.
- Phased manufacturing expansion plan over 5 years.
- Analytica pursuing public health markets for post-natal rehabilitation and aged care prevention.

6 September 2021. Analytica Ltd (ASX:ALT) wishes to update shareholders on its strategy to manufacture and supply its PeriCoach product to meet prospective demand, and financial support offered by the Queensland Government under its Advance Queensland Industry Attraction Fund (AQIAF).


Analytica's commercialisation process for the PeriCoach system to date has followed the path of R&D, product development, regulatory clearances, and conducting market research. During this phase, Analytica has outsourced manufacturing of the product.

With positive progress having been achieved on its commercialisation activities, such as the distribution agreement in the Middle East across 10 countries and the JV in China, Analytica has conducted a strategic review of its manufacturing strategy in contemplation of higher prospective demand for the PeriCoach product in North America and Europe currently being pursued.

Analytica has taken the decision to develop its own manufacturing capability and become the regulatory manufacturer-of-record for the PeriCoach product.

The benefits of bringing the PeriCoach product under Analytica's control include:

- **better supply chain management and regulatory compliance** - being better able to manage delays in global supply chains and restricted travel during the covid-19 pandemic and to comply with regulatory requirements (including new certifications and responsibilities imposed on manufacturers following recent rule changes in Europe and Australia regarding software in medical devices);
- **meet potential demand from distribution networks** – being better able to meet prospective demand for the PeriCoach product for Australian sales and export to the Middle East, European and US markets, with appropriate clearances; and
- **market re-engagement** – leveraging the 2020 published clinical trial results from the University of New Mexico with a clinical trial in peer reviewed publication and subsequent published health economic manuscript, Analytica will be well positioned to start re-engaging with the market. For example, it would provide the ability to re-commence direct to consumer sales and to continue to pursue deals with public health systems and health insurers to address the enormous women's health issues of rehabilitation of post-natal mothers and treatment for post-menopausal women to prevent or delay their entry into



residential aged care.

An internal manufacturing capacity will require the establishment of an ISO 13485 certified, and US QSR-compliant facility of our own.

Analytica has presented a detailed, staged manufacturing expansion plan over 5 years to the Queensland Government which has agreed to provide funding over the Project period under an AQIAF agreement.

Analytica's proposal to the Queensland Government involves establishing a headquarters in Maryborough, Queensland comprising manufacturing, warehousing, a customer support centre, data centre, and administration and training support for the production of the PeriCoach e-health system.

Initially, Analytica will accept supplied components and perform final assembly, quality control testing, packaging and product release. As volumes increase the plan allows for plastic and silicone moulding to be brought in-house, and at full implementation, electronics manufacturing.

Analytica's CEO and COO are experienced in managing medical device manufacturing and have been adapting the company's quality management system for in-house manufacturing over the last 12 months. Analytica has pre-arranged for a notified body to conduct an ISO13485 audit of Analytica facilities and quality system.

The AQIAF program was established in 2016 by the Queensland Government to provide financial incentives to attract projects assessed to provide significant economic benefits to Queensland. AQIAF specifically aims to drive job creation, regional growth, increased innovation and technology and supply chain development. Analytica's plan meets all these objectives.

"The Queensland Government is committed to encouraging investment in the biomedical and advanced manufacturing sectors, and we're thrilled to be supporting Analytica to execute its manufacturing strategy in Queensland." Treasurer and Minister for Investment Cameron Dick said.

Analytica Chairman Dr Michael Monsour said "We are excited to be establishing our headquarters, manufacturing and call centre operations in Maryborough. We are looking to secure a facility that we can fit-out to our specifications within the next 6 months."

Grant payments are made retrospectively on the completion of agreed milestones and there is no obligation on Analytica to continue the Project should circumstances change, noting the Queensland Government has the right to terminate the grant if Analytica is not able to meet the agreed milestones.

The AQIAF grant is being provided on standard AQIAF terms and conditions. In addition, various project specific grant preconditions must be met within 6 months including securing a site in Maryborough, entering into fit out contracts, securing Project funding for the first 3 years (including performance bank guarantees to the Queensland Government), an approved funding plan for the balance of the Project, continued TGA approval for the PeriCoach product, an approved workforce development plan and approved marketing, distribution and sales arrangements. Analytica is working constructively towards satisfaction of these preconditions but there is no guarantee or assurance that these preconditions will be satisfied either at all or on terms and conditions satisfactory to the Queensland Government or Analytica or that the grant funding will be made available.



Further information regarding the Project and its scope and funding will be made available when there is a reasonable basis to do so. Investors and shareholders should await receipt of that information to assess the operational and financial implications of the Project.

Authorised for release by the Board

For more information, please contact: investorrelations@analyticamedical.com

For more information about the PeriCoach System, visit: www.PeriCoach.com

For more information about Analytica, visit www.AnalyticaMedical.com

About Analytica Limited

Analytica is a product development and commercialisation company, based in Queensland, Australia, focussed on Class I and II medical device products.

Analytica's lead product is the PeriCoach® System – an e-health treatment system for women who suffer Stress Urinary Incontinence. This affects 1 in 3 women worldwide and is mostly caused by trauma to the pelvic floor muscles as a result of pregnancy, childbirth and menopause.

PeriCoach comprises a device, web portal and smartphone app. The device evaluates activity in pelvic floor muscles. This information is transmitted to a smartphone app and can be loaded to a cloud database where physicians can monitor patient progress via a web portal. This novel system enables physicians to remotely determine if a woman is performing her pelvic floor exercises and if these are improving her condition. Strengthening of the pelvic floor muscles can also potentially improve sexual sensation or satisfaction and orgasm potential in some women.

PeriCoach has regulatory clearance in Australia and has CE mark for Europe and USFDA 510(k) clearance for the treatment of urinary incontinence. Regulatory clearance in China and the Middle East is now underway.

PeriCoach also has clearance in Australia, and CE Marking in Europe for the treatment of mild to moderate pelvic organ prolapse, a condition that affects up to 1 in 5 women during their lifetime.

Analytica is also the developer of the Enhanced Infusion System (EIS), a combination of patented technologies developed under the project names AutoStart and AutoFlush. The EIS is a simple and inexpensive IV add-in technology to reduce nursing monitoring costs, reduce embolism risk, improve infection control, and automatically restart flow after medication delivery during intravenous fluid infusion.

